PathAI
About PathAI
PathAI is a leading healthcare AI company specializing in precision pathology, dedicated to improving patient outcomes through advanced artificial intelligence. The company develops robust, versatile solutions that leverage deep computational and medical expertise to optimize the analysis of patient tissue samples. Their core mission is to enhance diagnostic accuracy, accelerate drug development, and facilitate the matching of patients with the most effective treatments, particularly in complex diseases like cancer.
The company’s flagship platform, AISight®, is a cloud-native intelligent enterprise workflow solution designed for digital pathology. It serves as a central hub for case and image management, integrating best-in-class AI tools for various histopathology use cases. PathAI’s technology applies machine and deep learning techniques to vast datasets, including over 32.5 million expert annotations from a proprietary and crowd-sourced network of over 450 pathologists, to rigorously train and validate its AI-based models. This enables precise identification and quantification of pathological features, supporting pathologists in managing workloads and improving diagnostic standards.
PathAI collaborates extensively with biopharmaceutical companies, diagnostic laboratories, and academic medical centers, offering a comprehensive suite of services. These include AI-powered translational research for biomarker and drug discovery, end-to-end clinical trial pathology services, and support for diagnostic development and commercialization. Their solutions aim to unlock novel insights into disease pathophysiology, biomarker expression, and drug response at the tissue and cellular level, ultimately driving precision medicine forward.
Focus Areas
Business Intelligence
| Key Investors | General Catalyst, General Atlantic, Tiger Global Management, D1 Capital Partners, Kaiser Permanente, LabCorp, Bristol-Myers Squibb Company, Merck Global Health Innovation Fund, 8VC, Adage, Biospring Partners, KdT Ventures, Polaris Partners, Refactor Capital, Pillar VC |
| Partnerships | Quest Diagnostics (2024), MedStar Health (2026), Roche Tissue Diagnostics (expanded 2024), ConcertAI (2023), Agilent Technologies (2023), Foundation for the National Institutes of Health's Biomarkers Consortium (2023), University Hospital Zurich (2026), UMC Utrecht (2025), Labcorp (expanded 2026), Northwestern Medicine (2025), Precision for Medicine (2025), Deep Bio (2024), DoMore Diagnostics (2024), Paige (2024), Visiopharm (2024) |
| Acquisitions | Poplar Healthcare (2021) |
| Technology | AISight® Dx digital pathology platform, cloud-native, AI-powered research platform, machine learning, deep learning, computer vision, AI operating system, Predetermined Change Control Plan (PCCP), PLUTO foundation model |
| FDA Clearances | 1 cleared products (estimated) |
What Physicians Need to Know
For physicians, PathAI's solutions are designed to augment, not replace, their expertise. The AI-powered tools offer improved diagnostic accuracy and consistency by reducing inter- and intra-observer variability, leading to more reliable diagnoses. Pathologists can benefit from enhanced workflow efficiency through automated tasks like specimen orientation, case prioritization, and faster turnaround times. The platform provides deeper insights and facilitates biomarker discovery by extracting quantitative and spatial features from H&E slides, which can lead to a better understanding of disease pathophysiology. Crucially, PathAI's Explainable AI features provide visual overlays and justifications for AI predictions, empowering pathologists with confidence and a clear understanding of the AI's reasoning. This ultimately supports precision medicine by aiding in matching patients with the most effective treatments and accelerating drug development, leading to improved patient outcomes. The FDA clearances and designations for their platforms and algorithms further instill clinical confidence in the reliability and utility of these advanced tools. The cloud-native nature of AISight also enables seamless collaboration and remote access, which is increasingly vital in modern pathology practice.
PathAI's AISightu00ae platform is built as a cloud-native, open enterprise workflow solution, emphasizing broad interoperability. It is designed to integrate seamlessly with major Laboratory Information Systems (LIS/LIMS) and supports various slide scanners from leading vendors such as Leica Aperiou00ae, Hamamatsu NanoZoomeru00ae, and Roche VENTANAu00ae. PathAI actively fosters strategic partnerships across the digital pathology ecosystem to ensure its solutions can be easily adopted and integrated into diverse laboratory environments.
What the Web Says
PathAI is a company focused on improving patient outcomes through AI-powered pathology solutions, offering services from wet lab to algorithm deployment for clinical trials and diagnostics. Their platform utilizes AI to analyze high-resolution pathology slides, classify tissues, and compile diagnostic reports, aiming to enhance diagnostic efficiency and accuracy while accelerating drug development. The company has received regulatory approvals for select clinical diagnostic and research use cases globally, including FDA Breakthrough Device Designation for PathAssist Derm and 510(k) clearance for AISightu00ae Dx2. Employer reviews indicate a mission-driven culture with strong engineering talent, but also highlight challenges related to growth, management, and work-life balance for some roles.
Overall: MixedStrengths
- Top-notch mission and technology, with a singular vision.
- High-grade enterprise security and compliance standards for their product.
- Unrivaled tissue and cell classification depth.
- Saves time on manual slide analysis and reporting.
- Good compensation and benefits.
- Positive work culture with great team cohesion and opportunities for learning.
Limitations
- Growing pains typical of a company their size and age in an evolving, competitive industry.
- Disorganized and toxic vibe reported by some employees, with budgeting worries.
- Management's unfamiliarity with lab instruments and HR's mishandling of serious issues.
- Brutal and hard-to-adjust-to hours for some roles, like Pathologists' Assistants.
- Product requires custom enterprise contract configurations, leading to a high barrier to entry.
- Model outputs require clinical verification against source slides.
Based on reviews from: Indeed.com, Comparably, Elion Health, Great Place To Worku00ae, Build Fast with AI, Reddit, Becker's Hospital Review
Last updated: 2026-07-22
Videos
News, demos, and interviews about PathAI.
Videos load interactively. If none appear, search YouTube for PathAI →
Press & Coverage
Frequently Asked Questions
Investors
Who's funded PathAI.
Related Companies
Intelligent Voice AI (IVAI) is an agentic AI platform that deploys AI voice agents specifically designed for healthcare, insurance, legal, and home services businesses. For physicians and medical practices, IVAI’s Evolve AI Agents act as an AI workforce, not just an answering service, handling a comprehensive range of administrative and operational tasks. These agents can […]
Dext, formerly known as Receipt Bank, is a company that specializes in bookkeeping automation, leveraging data, technology, and applied AI to enhance productivity and efficiency for businesses, accountants, and bookkeepers. [3, 16] Their platform is designed to streamline financial document management and automate bookkeeping tasks, aiming to simplify the accounting process and enable more informed […]
Cortex (https://www.cortex.app) is an AI-powered internal developer portal designed to enhance engineering excellence and streamline software development workflows. For physicians, this translates to a platform that can indirectly improve healthcare technology by enabling engineering teams to build more reliable, secure, and efficient software. The platform helps in cataloging, scoring, and assigning actions to improve service […]
Nino is an AI-powered financial planning and tax service that aims to provide comprehensive financial guidance. For physicians, Nino’s AI software can help manage income, student loans, and plan career transitions, such as moving from training to practice or considering practice ownership. The platform allows physicians to view loans, income, and savings in one place, […]
Coral AI is a healthcare artificial intelligence company that aims to streamline administrative workflows for healthcare providers, ultimately accelerating patient access to care. The company’s AI-driven platform integrates with existing healthcare systems, including EHRs, fax lines, and payer portals, to automate complex administrative tasks. This includes patient intake, prior authorizations, billing, compliance, and patient outreach. […]
SamaCare is a healthcare AI company that provides a cloud-based workflow intelligence platform designed to streamline the prior authorization process for specialty medications. The company’s platform aims to reduce the administrative burden on medical practices, improve approval rates, and add predictability to patient care. By digitizing the often manual and paper-heavy prior authorization process, SamaCare […]